MOMENTUM IN OUR DYNAMIC PIPELINE BASED ON EMERGING DATA



1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval
2. Potential for data driven acceleration of some Wave 2 programs into Wave 1
3. Approval date assumes filing on Phase 2 data
4. Pending deal close

All timelines are approximate estimates as of October 29, 2020.

For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1 & 2	PHASE 3	FILED
ONCOLOGY	**NINLARO®** Proteasome inhibitor R/R MM triplet Tx (US, EU) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL) **NINLARO®** Proteasome inhibitor R/R MM doublet Tx (US, EU)	**ALUNBRIG®** ALK inhibitor 1L ALK+NSCLC (CN) **NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (US, EU) **ICLUSIG®** BCR-ABL inhibitor FL Ph+ ALL (US) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)	**NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (JP) **ALUNBRIG®** ALK inhibitor 1L & 2L ALK+NSCLC (JP) **ADCETRIS®** *Seattle Genetics* CD30 ADC CTCL (CN) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L HCC (JP) **ICLUSIG®** BCR-ABL inhibitor TKI res. chronic phase CML (US) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP) **Niraparib** *GlaxoSmithKline* PARP 1/2 inhibitor Ovarian cancer – maint. (JP) **Niraparib** *GlaxoSmithKline* PARP 1/2 inhibitor Ovarian cancer – salvage (JP)
RARE GENETIC & HEMATOLOGY	**NATPARA** PTH replacement Hypothyrodism (JP)	**TAKHZYRO** Anti-kallikrein mAb HAE pediatric (GL) **OBIZUR** *Ipsen* FVIII replacement CHAWI (US, EU) **VONVENDI** vWF replacement vWD Adult Prophylaxis (GL) **TAKHZYRO** Anti-kallikrein mAb HAE (JP) **TAKHZYRO** Anti-kallikrein mAb BMA (GL) **VONVENDI** vWF replacement vWD Pediatric on-demand (GL) **ADYNOVATE** Pediatric HemA (EU)	**TAKHZYRO** Anti-kallikrein mAb HAE prophylaxis (CN)
NEUROSCIENCE			**BUCCOLAM**[1] GABA Allosteric Modulator Status Epilepticus (JP)
GASTRO-ENTEROLOGY	**ENTYVIO®** α4β7 mAb Pediatric UC/CD (GL)	**ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (US, JP) **Vonoprazan** PCAB Oral disintegrated tablet formulation (JP) **ENTYVIO®** α4β7 mAb GvHD Prophylaxis (EU, JP) **ENTYVIO®** α4β7 mAb SubQ CD (US, JP) **Vonoprazan** PCAB H. Pylori (CN)	**ENTYVIO®** α4β7 mAb SubQ UC (US, JP) **Vonoprazan** PCAB Reflex Esophagitis Maintenance (CN) **GATTEX** GLP-2R agonist Pediatric-SBS (JP) **Vonoprazan** PCAB Duodenal ulcer (CN) **GATTEX** GLP-2R agonist Adult-SBS (JP)
PLASMA-DERIVED THERAPIES		**CUVITRU** IgG 20% (human) subcutaneous PID (JP) **HYQVIA** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU) **HYQVIA** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)	**HYQVIA** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase SID (EU)

- Orphan Drug Designation (in any region / indication for a given asset)
- Potential for registration enabling Ph-2 study
- Clinical stage up since Q1 FY20
- Approved since Q1 FY20

Pipeline as of October 29, 2020; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas

1. In October 2020, Takeda completed the sale of Buccolam to a subsidiary of Neuraxpharm Group (Neuraxpharm). For a defined period, Takeda will continue to provide certain services to Neuraxpharm, including serving as the Japanese marketing authorization holder/